Friday, 16 October 2026European Markets

MYHOTELMATCH Soars 34% In Tuesday Trading

Loading stream...

(vianews) - investors were pleased to hear this news, sending myhotelmatch stock up by 34.33% to eur0.90 at 15:24 est on tuesday afternoon - following on a strong showing in monday's session when the cac 40 index also rose by 0.47% - this recent gain saw myhotelmatch's stock fall 82.73% since its 52-week high of eur3.88.

about myhotelmatch

myhotelmatch s.a. of biot, france has designed an advanced online hotel reservation platform using artificial intelligence (ai). operating as an online travel agency that takes inspiration from online dating services, myhotelmatch's goal since 2010 has been to revolutionize how travelers book hotels through ai-powered personalization to provide tailored hotel recommendations tailored specifically to them.

yearly analysis

based on available information, myhotelmatch stock is currently trading at eur0.90; significantly below its 52-week high of eur3.88 but higher than its 52-week low of eur0.64. this indicates a significant drop in value over the last year. myhotelmatch anticipates sales growth of 78% this year and 14.3% for next year - this shows revenue increase at an above-average rate in the near future. overall, this information suggests that myhotelmatch's stock may represent an attractive high-risk/high-reward investment opportunity, particularly for investors willing to risk investing in companies with a history of volatility and are hopeful about future growth prospects of myhotelmatch. before making any decisions based on this data alone, investors should conduct extensive research to gauge their personal risk tolerance as well as any goals for investing they may have set themselves.

technical analysis

myhotelmatch's stock has seen substantial fluctuations over the past several weeks, rising above its 50-day moving average of eur0.89 but remaining far below its 200-day moving average of eur1.65. additionally, its last reported volume of 28,144 is significantly greater than its usual volume of 8,745, suggesting increased trading activity. myhotelmatch experienced negative variations of 5.44% in the past week, 1.76% in the prior month and 2.54% over its past three months; its highest amplitude of average volatility over that time span was 7.62% for its highest amplitude occurring once every week (3.45% in each subsequent month and 2.54% annually). according to the stochastic oscillator, myhotelmatch stock is currently considered overbought (>=80), signaling potential decline in its value over the near future. furthermore, its stock has experienced considerable fluctuations, prompting investors to be wary when making investment decisions.

equity analysis

earnings per share (eps) is a financial metric used to measure how much profit a company generates per outstanding share. a negative eps indicates a loss during the trailing twelve months period - in the case of myhotelmatch this means eur-1.07. investors may find this information beneficial as it gives insight into a company's financial health and ability to generate profits for shareholders; but bear in mind that negative eps does not always indicate it has underperformed; instead it could simply reflect growth or investment into new opportunities that arises.

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com